Glioblastoma
2.3K views | +4 today
Follow
 
Scooped by Beeyond
onto Glioblastoma
Scoop.it!

Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma Therapy

Dendritic Cell Vaccines Offer Promising Signals as Glioblastoma Therapy | Glioblastoma | Scoop.it
Currently, Moffitt Cancer Center is participating in a multicenter phase III randomized double- blind clinical trial examining the efficacy of a DC vaccine, DCVax-L, derived from autologous DCs pulsed with GBM lysates (NCT00045968).22 The study, which began in December 2006, seeks to randomize 300 patients with newly diagnosed grade IV GBM in a 2:1 ratio to receive either DCVax-L or placebo. Participants are screened for the trial before they undergo surgical resection of the tumor; they then receive standard therapy, including radiation and temozolomide, before proceeding to randomization.
more...
No comment yet.
Your new post is loading...
Your new post is loading...
Scooped by Beeyond
Scoop.it!

Survival Analysis of Glioblastoma Multiforme

Survival Analysis of Glioblastoma Multiforme | Glioblastoma | Scoop.it
The MST of the patients who had post-operative CCRT with or without adjuvant TMZ was better than the PORT group. The RPA classification can be used to predict survival. Multimodality therapy demonstrated the most effective treatment outcome. Temozolomide might be beneficial for GBM patients in order to increase survival time.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial | Glioblastoma | Scoop.it
Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor vaccines. In this multicentric randomized open-label phase II study, we investigated the efficacy of vaccination with tumor lysate-charged autologous DCs (Audencel) in newly diagnosed glioblastoma multiforme (GBM).
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Zika Virus Weapon Against Glioblastoma

Zika Virus Weapon Against Glioblastoma | Glioblastoma | Scoop.it

The report was published by researchers from the University of Texas Medical Branch, who have been researching into the Zika virus for years. The researchers have been attempting to find out how the virus attacks the brain. Glioblastoma multiforme, GBM, is regarded as the most dangerous form of brain cancer, as most patients die within two years after diagnosis.

Beeyond's insight:

Researchers found that a live-attenuated Zika vaccine with a weakened version of the virus could kill GBM stem cells without causing disease in humans. “Research has shown that the Zika vaccine could prolong the lives of mice with human GBM without damaging the brain or altering their behaviour.
“However, that is far from enough, [...] we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.”

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Tumor Ablation with Chemo-Radiotherapy Consolidation Yields Rare Durable Glioblastoma Remission

Tumor Ablation with Chemo-Radiotherapy Consolidation Yields Rare Durable Glioblastoma Remission | Glioblastoma | Scoop.it
Although stereotactic brain biopsy can provide accurate and safe diagnosis of deep brain lesions owing to the small diameter of the biopsy instrument, it does not provide meaningful cytoreduction of tumor cells. In some cases, a safe corridor can be devised via a minimally invasive craniotomy using neuronavigation (with or without tubular retractors), but the location in this case was not accessible without a high risk of sustained functional morbidity for the patient’s right lower limb. A noninvasive treatment such as stereotactic radiosurgery eliminates the access issue but has been shown not to improve prognosis as part of the initial management of glioblastoma.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Vaccine Meant for Zika Could Lead to Brain Cancer Treatment

Vaccine Meant for Zika Could Lead to Brain Cancer Treatment | Glioblastoma | Scoop.it

A modified version of the vaccine was shown to destroy cancer cells in mice with glioblastoma while leaving healthy cells behind. 

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

VTCRI research team identifies a potential strategy in fight against brain cancer 

VTCRI research team identifies a potential strategy in fight against brain cancer  | Glioblastoma | Scoop.it

VTCRI researchers determined when an enzyme produced by a member of a gene family associated with circadian rhythms (stained green in the image of glioblastoma cells) is blocked, the proliferation of cancer stem cells stops and tumor formation in laboratory models is inhibited. Image from the Human Protein Atlas.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Stem cells show promise as drug delivery tool for childhood brain cancer

Stem cells show promise as drug delivery tool for childhood brain cancer | Glioblastoma | Scoop.it

The latest in a series of laboratory breakthroughs could lead to a more effective way to treat the most common brain cancer in children. Scientists from the University of North Carolina Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, and the UNC School of Medicine reported results from early studies that demonstrate how cancer-hunting stem cells, developed from skin cells, can track down and deliver a drug to destroy medulloblastoma cells hiding after surgery.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Epigenetic analysis of aggressive brain tumors 

Epigenetic analysis of aggressive brain tumors  | Glioblastoma | Scoop.it

Glioblastoma is a highly aggressive brain cancer that predominantly affects people in their 50s, 60s and 70s. Even under the best available care, half of the patients die within one year after diagnosis, and very few live on for more than three years. Many efforts to develop new, targeted treatments have failed over the last decade. The high degree of molecular heterogeneity among the cancer cells results in evolutionary selection for those cells that can withstand drug treatment.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Sen. John McCain's illness: What to know about glioblastoma

Sen. John McCain's illness: What to know about glioblastoma | Glioblastoma | Scoop.it
Glioblastoma multiforme is a tumor that develops in the connective tissue of the brain, originating in brain cells called astrocytes. It is a relatively rare disease that doctors estimate strikes only 3 in 100,000 people. The cancer is most commonly found in patients older than 60. Unlike many other cancers, glioblastoma does not spread to other organs; instead, it remains in the brain, growing quickly and invading surrounding tissues. As the cancerous cells multiply, their growth affects the rest of the brain by compressing adjacent structures.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Can we fine-tune drug doses with the help of artificial intelligence?

Can we fine-tune drug doses with the help of artificial intelligence? | Glioblastoma | Scoop.it

Patients with glioblastoma, a malignant tumor in the brain or spinal cord, typically live no more than five years after receiving their diagnosis. And those five years can be painful — in an effort to minimize the tumor, doctors often prescribe a combination of radiation therapy and drugs that can cause debilitating side effects for patients.
Now, researchers from MIT Media Lab have developed artificial intelligence (AI) that can determine the minimum drug doses needed to effectively shrink glioblastoma patients’ tumors.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing

Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing | Glioblastoma | Scoop.it
A significant fraction of LTS GBM patients had tumors with 1 or more alterations in the relevant GBM signaling pathways (RTK/PI3K, TP53 and RB1). In these patients, the PDGFRA alteration is suggested to be a favorable molecular factor. Our findings here are relevant for developing future targeted therapies and for identifying molecular prognostic factors in GBM patients.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

CAR T-cell therapy ‘quite promising’ for glioblastoma

CAR T-cell therapy ‘quite promising’ for glioblastoma | Glioblastoma | Scoop.it
Although progress with chimeric antigen receptor (CAR) T-cell therapy for solid tumors has been limited, clinical trials have demonstrated the feasibility and safety of the approach for treatment of glioblastoma.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21%

Poliovirus Therapy for Recurrent Glioblastoma Has 3-Year Survival Rate of 21% | Glioblastoma | Scoop.it
Comparatively, just 4 percent of patients at Duke with the same type of recurring brain tumors were alive at three years when undergoing the previously available standard treatment.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

The potential for Remodelling the Tumour Vasculature in Glioblastoma

The potential for Remodelling the Tumour Vasculature in Glioblastoma | Glioblastoma | Scoop.it
Despite significant improvements in the clinical management of glioblastoma, poor delivery of systemic therapies to the entire population of tumour cells remains one of the biggest challenges in the achievement of more effective treatments. On the one hand, the abnormal and dysfunctional tumour vascular network largely limits blood perfusion, resulting in an inhomogeneous delivery of drugs to the tumour. On the other hand, the presence of an intact blood-brain barrier (BBB) in certain regions of the tumour prevents chemotherapeutic drugs from permeating through the tumour vessels and reaching the diseased cells.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

TEAD1 Identified As Regulator Of Glioblastoma Tumor Migration

TEAD1 Identified As Regulator Of Glioblastoma Tumor Migration | Glioblastoma | Scoop.it

The finding may help increase the success rate and overall survival time after surgery for patients who are afflicted with this devastating form of tumor.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Zika virus shows promise for treating deadly brain cancer

Zika virus shows promise for treating deadly brain cancer | Glioblastoma | Scoop.it
Researchers have used a genetically modified Zika virus strain to kill GBM stem cells in preclinical laboratory models. While further research is needed, it is hoped that immunotherapies like this might lead to improved treatment for brain cancer patients
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Zika virus vaccine shows promise for treatment of fatal glioblastoma

Zika virus vaccine shows promise for treatment of fatal glioblastoma | Glioblastoma | Scoop.it
An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice. In a study published this week in mBio®, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival

Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival | Glioblastoma | Scoop.it
Together, our results demonstrate that CK1ε regulates the survival of glioblastoma cells and glioblastoma stem cells through β-catenin signaling, underscoring the importance of targeting CK1ε as an effective treatment for glioblastoma.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Research team identifies a potential strategy in fight against brain cancer

Research team identifies a potential strategy in fight against brain cancer | Glioblastoma | Scoop.it

Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Glioblastoma Multiforme: Practice Essentials, Background, Pathophysiology

Glioblastoma Multiforme: Practice Essentials, Background, Pathophysiology | Glioblastoma | Scoop.it
Glioblastoma multiforme (GBM) is by far the most common and most malignant of the glial tumors. Even with optimal therapy, median survival is only about 12 months
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

The brain cancer that killed McCain is hard to treat–& What is Glioblastoma?

The brain cancer that killed McCain is hard to treat–& What is Glioblastoma? | Glioblastoma | Scoop.it

There has been little progress in developing new U.S. Food and Drug Administration-approved drugs since McCain’s former Senate colleague, Ted Kennedy, succumbed to the same type of brain cancer in 2009. And it remains deadly: Half of patients with glioblastoma die within 15 months.
Nonetheless, doctors are constantly testing new drugs and drug combinations to slow the growth of these tumors after standard treatments of radiation and chemotherapy have failed.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Glioblastoma treatment: what it looks like

Glioblastoma treatment: what it looks like | Glioblastoma | Scoop.it
Average survival for malignant glioblastoma tends to be about 14 months with treatment -- and it is difficult to treat, according to CNN Chief Medical Correspondent Dr. Sanjay Gupta, a practicing neurosurgeon.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

A targeted approach to treating glioma

A targeted approach to treating glioma | Glioblastoma | Scoop.it
Researchers from MIT, Brigham and Women’s Hospital, and Massachusetts General Hospital have developed a new way to treat low-grade glioma. They devised a test that can rapidly check for the IDH mutation during brain surgery, and if the mutation is present, they can implant microparticles that gradually release an IDH-targeted drug over several days or weeks.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Immune phenotypes predict survival in patients with glioblastoma multiforme

Immune phenotypes predict survival in patients with glioblastoma multiforme | Glioblastoma | Scoop.it
Defined alterations of the immune system may guide the course of disease in patients with GBM and may be prognostically valuable for longitudinal studies or can be applied for immune intervention.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Treating Cancer with Modified Viruses – What is Oncolytic Virus Therapy?

Treating Cancer with Modified Viruses – What is Oncolytic Virus Therapy? | Glioblastoma | Scoop.it
“It appears that the use of viruses in the treatment of cancer was not the result of some perspicacious theory of an alternative therapy but rather just stemmed from the observation that, occasionally, cancer patients who contracted an infectious disease went into brief periods of clinical remission. In the case of leukemia, it was well recognized that contraction of influenza sometimes produced beneficial effects. Although no cases were reported where an accompanying infectious disease led to complete cure of leukemia, it was anticipated that a treatment based upon the causal agent of infection would provide an alternative to the “hopelessness of the ordinary treatment of leukemia.”
more...
No comment yet.